What is an endolymphatic sac tumour?
An endolymphatic sac tumour (ELST) is a rare, slow-growing cancer of the inner ear region. It starts in the endolymphatic sac, a small pouch of tissue that lies against the back of the temporal bone, the hard bone that houses the hearing and balance organs. The sac is connected to the inner ear by a thin channel and helps regulate the fluid inside it.
Under the microscope, an ELST is a low-grade adenocarcinoma, a cancer of gland-forming cells (Mendenhall et al., 2018). It grows very slowly, but over time it erodes bone and can extend into the inner ear, the middle ear, the base of the skull and the space around the brainstem. Spread to lymph nodes or distant organs is extremely unusual.
Most people with an ELST first notice hearing loss on one side and ringing in the ear (tinnitus). Later, there may be dizziness, unsteadiness or weakness of the face. Because these symptoms are common and develop gradually, the diagnosis is often made late.
ELSTs can occur on their own (sporadic) or as part of von Hippel-Lindau (VHL) disease, an inherited condition that causes tumours in several organs. In a large review, about one in four people with ELST had VHL (Tang et al., 2023). Complete surgical removal is the standard treatment, and long-term follow-up is needed because the tumour can return many years later.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Low-grade papillary adenocarcinoma of the endolymphatic sac |
| Location | Back of the temporal bone, near the inner ear |
| How common | Very rare; a few hundred cases described |
| Typical age | Often 30s-50s; younger in VHL disease |
| VHL link | About 1 in 4 cases; may affect both ears |
| Main symptoms | One-sided hearing loss, tinnitus, dizziness |
| Spread | Local bone destruction; distant spread very rare |
| Main treatment | Complete surgical removal; radiotherapy for residual disease |
| Outlook | Survival is good, but recurrence and hearing loss are common |
2. Types of endolymphatic sac tumour
| Type | Description |
|---|---|
| Sporadic ELST | Occurs without VHL disease; usually one side |
| VHL-associated ELST | Occurs in people with VHL disease; may be found earlier through surveillance, and can affect both ears |
In the review by Tang and colleagues, VHL-associated tumours were diagnosed at a younger age than sporadic ones, and they affected women more than twice as often as men (Tang et al., 2023).
How it compares with other ear and skull base tumours
| Tumour | Key features |
|---|---|
| Endolymphatic sac tumour | Behind the inner ear; erodes bone; papillary under the microscope |
| Vestibular schwannoma (acoustic neuroma) | Benign nerve sheath tumour in the internal auditory canal |
| Paraganglioma (glomus tumour) | Vascular tumour in the middle ear or jugular area; often causes pulsating tinnitus |
| Meningioma | Arises from the brain coverings |
| Middle ear adenoma | Benign gland tumour of the middle ear |
| Metastasis | Spread from another cancer, such as kidney cancer |
3. Causes and risk factors
| Factor | Notes |
|---|---|
| Von Hippel-Lindau disease | The main known risk factor; caused by inherited variants in the VHL gene |
| Sporadic VHL gene changes | Some tumours without inherited VHL carry VHL changes in the tumour only |
| Age | Most often in early to middle adulthood |
VHL disease predisposes people to several tumours, including haemangioblastomas of the brain, spinal cord and retina, kidney cancer, phaeochromocytoma, pancreatic neuroendocrine tumours and ELST (Binderup et al., 2022). Anyone diagnosed with an ELST is usually offered genetic testing for VHL.
What VHL surveillance involves
People with VHL disease are offered regular checks from childhood, covering the retina, brain and spinal cord, inner ear, kidneys, adrenal glands and pancreas (Binderup et al., 2022). For the ear, this usually means hearing tests and, at intervals, MRI of the inner ear region. Finding an ELST while it is still small gives the best chance of keeping useful hearing.
4. How does it look
On CT scans
| Feature | Description |
|---|---|
| Location | Back surface of the petrous temporal bone, between the internal auditory canal and the sigmoid sinus |
| Bone | Moth-eaten erosion of bone |
| Inside the tumour | Small specks or spicules of bone |
| Edge | Sometimes a thin rim of calcification |
On MRI
| Feature | Description |
|---|---|
| Signal | Mixed; bright spots on T1-weighted images from bleeding or protein-rich fluid |
| Enhancement | Patchy uptake of contrast |
| Inner ear | Bleeding into the inner ear fluid spaces may be seen and can explain sudden hearing loss |
| Extent | Shows spread into the skull base, middle ear and around the brainstem |
Under the microscope
| Feature | Description |
|---|---|
| Pattern | Papillary and glandular structures |
| Cells | A single layer of cuboidal or columnar cells, often with clear cytoplasm |
| Spaces | Cystic spaces containing a pink, thyroid-like fluid |
| Blood vessels | Very vascular tumour |
| Stains | Positive for cytokeratins, EMA, PAX8 and CAIX |
5. Symptoms
Common symptoms
- Hearing loss in one ear, gradual or sudden
- Tinnitus (ringing or buzzing)
- Feeling of fullness in the ear
- Dizziness or vertigo
Less common symptoms
| Symptom | What it may mean |
|---|---|
| Unsteadiness (ataxia) | Pressure on the balance system or cerebellum |
| Facial weakness | Involvement of the facial nerve |
| Ear pain or discharge | Spread into the middle ear or ear canal |
| A mass seen behind the eardrum | Tumour in the middle ear |
| Headache | Large tumour |
| Difficulty swallowing or hoarseness | Spread to the lower cranial nerves |
The symptoms can resemble Meniere’s disease, which may lead to delays in diagnosis.
In a pooled analysis, almost three in ten patients already had some facial nerve weakness before surgery (Gioacchini et al., 2023).
When to seek medical advice
See a doctor or an ear, nose and throat (ENT) specialist if you have hearing loss on one side, persistent tinnitus, recurrent vertigo or facial weakness. If you have VHL disease, report any change in hearing promptly, even between scheduled checks.
6. Diagnosis
| Test | Purpose |
|---|---|
| Hearing tests (audiometry) | Measures hearing in each ear |
| Balance testing | Assesses the inner ear balance organs |
| CT of the temporal bone | Shows bone erosion |
| MRI with contrast | Shows the tumour’s extent and inner ear bleeding |
| Angiography | Maps the blood supply; may be used for embolisation before surgery |
| Biopsy | Often made at surgery rather than beforehand |
| Genetic testing for VHL | Recommended for everyone with ELST |
| VHL screening scans | Checks the brain, spine, eyes, kidneys, adrenals and pancreas if VHL is confirmed |
Staging
There is no TNM stage for ELST. Surgeons often describe tumours by their extent:
| Extent | Description |
|---|---|
| Limited | Confined to the temporal bone behind the inner ear |
| Middle ear | Extends into the middle ear |
| Skull base | Spreads into the jugular foramen, petrous apex or clivus |
| Intracranial | Extends into the space around the brain |
Larger tumours are harder to remove completely and carry a higher risk of nerve damage.
7. Treatment
Treatment is planned by a skull base team, including neuro-otologists, neurosurgeons and radiation oncologists.
Surgery
Complete removal with clear margins is the standard of care (Tang et al., 2023). The approach depends on the tumour’s size and the person’s hearing.
| Approach | When it is used |
|---|---|
| Retrolabyrinthine or transmastoid approach | Small tumours, aiming to preserve hearing |
| Translabyrinthine approach | Larger tumours when hearing is already lost |
| Infratemporal fossa or combined approaches | Tumours reaching the skull base |
| Embolisation before surgery | Reduces bleeding from this very vascular tumour |
Surgery was the main treatment in almost nine in ten cases in the largest review (Tang et al., 2023).
Radiotherapy
| Situation | Role |
|---|---|
| Positive margins or residual tumour | Radiotherapy or stereotactic radiosurgery |
| Tumour that cannot be removed | Main treatment |
| Recurrence | Further surgery or radiotherapy |
There is no strong evidence for routine radiotherapy after complete removal (Tang et al., 2023).
Early treatment in VHL disease
In people with VHL, small tumours found on surveillance scans can be removed before hearing is lost. This is a key reason for regular inner ear checks in VHL.
Drug treatment
Belzutifan, a drug that blocks HIF-2 alpha, is approved for some VHL-related tumours, and its effect on ELST is being studied. Otherwise there is no standard drug treatment.
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Hearing loss, dizziness, facial weakness, leak of brain fluid, tinnitus |
| Radiotherapy | Tiredness, hair loss over the treated area, worsening hearing |
In pooled data, facial nerve weakness of some degree after surgery was common, but surgery worsened facial function in only a small proportion of patients (Gioacchini et al., 2023).
Hearing and balance rehabilitation
| Option | What it offers |
|---|---|
| Conventional hearing aid | Helps if some hearing remains in the affected ear |
| CROS hearing aid | Sends sound from the deaf side to the hearing ear |
| Bone-anchored hearing device | Transmits sound through the skull to the other ear |
| Cochlear implant | Considered in selected people, especially with hearing loss in both ears |
| Vestibular rehabilitation | Exercises that help the brain adapt to balance loss |
| Tinnitus therapy | Sound therapy and counselling to reduce distress |
Most people adapt well to hearing loss on one side, although noisy places and telling where sounds come from can be harder.
8. Outlook (prognosis)
ELSTs rarely threaten life, but they can cause lasting disability through hearing loss, imbalance and facial weakness.
| Measure | Reported results |
|---|---|
| Recurrence after treatment | Around 14-16% |
| Residual tumour after surgery | Around 1 in 6 |
| Time to recurrence | Average over 4 years; range from months to 20 years |
| Overall cure | Probably in the range of half to three-quarters, depending on extent (Mendenhall et al., 2018) |
| Factor | Effect |
|---|---|
| Small tumour | Better chance of cure and hearing preservation |
| Complete removal | Lowest risk of recurrence |
| Extensive skull base spread | Higher risk of residual disease |
| Early detection in VHL | Better hearing outcomes |
9. Follow-up
| Follow-up | Purpose |
|---|---|
| MRI every 6-12 months at first | Looks for residual or recurrent tumour |
| Then yearly or every 2 years | Long-term monitoring |
| Hearing tests | Monitor hearing in both ears |
| Facial nerve assessment | If weakness is present |
| VHL surveillance | Regular checks of the eyes, brain, spine, kidneys, adrenals and pancreas |
Because recurrences can appear many years after treatment, follow-up usually continues for at least 10 years and often for life (Tang et al., 2023).
10. Living with an endolymphatic sac tumour
- Ask about hearing aids or a bone-anchored hearing device if hearing is lost
- Do vestibular (balance) exercises if you have dizziness
- Protect your eye if facial weakness stops it from closing fully
- Take care with driving until dizziness has settled
- Keep up VHL surveillance if you have VHL disease
- Tell relatives about VHL testing if you carry a VHL variant
- Seek support from VHL and hearing loss organisations
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it cancer? | Yes, a low-grade adenocarcinoma, but it very rarely spreads |
| Will I lose my hearing? | Hearing loss is common; early removal of small tumours gives the best chance of saving it |
| Is it inherited? | Only when it is part of VHL disease |
| Can it occur in both ears? | Yes, mainly in people with VHL |
| Will I need radiotherapy? | Only if the tumour cannot be fully removed or comes back |
| Can it come back years later? | Yes, which is why long follow-up is needed |
| Should my family be tested? | If you have VHL, first-degree relatives are usually offered testing |
| Will I be able to drive? | Usually yes once any dizziness has settled; check local rules |
| Is surgery dangerous? | It is major skull base surgery, but serious complications are uncommon in experienced centres |
12. Questions to ask your care team
- Has my tumour affected my inner ear or facial nerve?
- Can it be completely removed, and can my hearing be preserved?
- Should I have embolisation before surgery?
- Do I need genetic testing for VHL?
- Will I need radiotherapy?
- How long will follow-up scans continue?
- What hearing rehabilitation options are available to me?
Resources
- Binderup, M.L.M. et al. (2022) ‘von Hippel-Lindau disease: updated guideline for diagnosis and surveillance’, European Journal of Medical Genetics, 65(8), 104538.
- Gioacchini, F.M. et al. (2023) ‘Surgical management of endolymphatic sac tumor: a systematic review and meta-analysis’, Journal of International Advanced Otology, 19(3), pp. 248-254.
- Mendenhall, W.M. et al. (2018) ‘Current treatment of endolymphatic sac tumor of the temporal bone’, Advances in Therapy, 35(7), pp. 887-898.
- Tang, J.D. et al. (2023) ‘Systematic review of endolymphatic sac tumor treatment and outcomes’, Otolaryngology-Head and Neck Surgery, 168(3), pp. 282-290.
Prepared by the editorial team, October 2026.